Literature DB >> 17846506

Kinetics of binding of LPS to recombinant CD14, TLR4, and MD-2 proteins.

Han Jae Shin1, Hayyoung Lee, Jong Dae Park, Hak Chul Hyun, Hyung Ok Sohn, Dong Wook Lee, Young Sang Kim.   

Abstract

TLR4 together with CD14 and MD-2 forms a pattern recognition receptor that plays an initiating role in the innate immune response to Gram-negative bacteria. Here, we employed the surface plasmon resonance technique to investigate the kinetics of binding of LPS to recombinant CD14, MD-2 and TLR4 proteins produced in insect cells. The dissociation constants (KD) of LPS for immobilized CD14 and MD-2 were 8.7 microM, and 2.3 microM, respectively. The association rate constant (Kon) of LPS for MD-2 was 5.61 x 10(3) M-1S-1, and the dissociation rate constant (Koff) was 1.28 10 2 S 1, revealing slow association and fast dissociation with an affinity constant KD of 2.33 x 10-6 M at 25 degreesC. These affinities are consistent with the current view that CD14 conveys LPS to the TLR4/MD-2 complex.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17846506

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  35 in total

1.  Soluble forms of Toll-like receptor 4 are present in human saliva and modulate tumour necrosis factor-alpha secretion by macrophage-like cells.

Authors:  S L Zunt; L V Burton; L I Goldblatt; E E Dobbins; M Srinivasan
Journal:  Clin Exp Immunol       Date:  2009-03-09       Impact factor: 4.330

2.  NETWORKS, BIOLOGY AND SYSTEMS ENGINEERING: A CASE STUDY IN INFLAMMATION.

Authors:  P T Foteinou; E Yang; I P Androulakis
Journal:  Comput Chem Eng       Date:  2009-12-10       Impact factor: 3.845

3.  Natural phosphoryl and acyl variants of lipid A from Neisseria meningitidis strain 89I differentially induce tumor necrosis factor-alpha in human monocytes.

Authors:  Constance M John; Mingfeng Liu; Gary A Jarvis
Journal:  J Biol Chem       Date:  2009-06-15       Impact factor: 5.157

4.  Distinct single-cell signaling characteristics are conferred by the MyD88 and TRIF pathways during TLR4 activation.

Authors:  Zhang Cheng; Brooks Taylor; Diana R Ourthiague; Alexander Hoffmann
Journal:  Sci Signal       Date:  2015-07-14       Impact factor: 8.192

Review 5.  Microbe-inducible trafficking pathways that control Toll-like receptor signaling.

Authors:  Yunhao Tan; Jonathan C Kagan
Journal:  Traffic       Date:  2016-11-23       Impact factor: 6.215

6.  Funiculosin variants and phosphorylated derivatives promote innate immune responses via the Toll-like receptor 4/myeloid differentiation factor-2 complex.

Authors:  Naoki Okamoto; Keisuke Mizote; Hiroe Honda; Akinori Saeki; Yasuharu Watanabe; Tomomi Yamaguchi-Miyamoto; Ryutaro Fukui; Natsuko Tanimura; Yuji Motoi; Sachiko Akashi-Takamura; Tatsuhisa Kato; Shigeto Fujishita; Takahito Kimura; Umeharu Ohto; Toshiyuki Shimizu; Takatsugu Hirokawa; Kensuke Miyake; Koichi Fukase; Yukari Fujimoto; Yoshinori Nagai; Kiyoshi Takatsu
Journal:  J Biol Chem       Date:  2017-07-28       Impact factor: 5.157

7.  The role of the hypothalamic-pituitary-adrenal axis in modulating seasonal changes in immunity.

Authors:  Kamau Pierre; Naomi Schlesinger; Ioannis P Androulakis
Journal:  Physiol Genomics       Date:  2016-06-24       Impact factor: 3.107

8.  A simple mathematical model of signaling resulting from the binding of lipopolysaccharide with Toll-like receptor 4 demonstrates inherent preconditioning behavior.

Authors:  Beatrice Rivière; Yekaterina Epshteyn; David Swigon; Yoram Vodovotz
Journal:  Math Biosci       Date:  2008-10-11       Impact factor: 2.144

Review 9.  A clear and present danger: endogenous ligands of Toll-like receptors.

Authors:  Jacob A Sloane; Daina Blitz; Zachary Margolin; Timothy Vartanian
Journal:  Neuromolecular Med       Date:  2009-10-14       Impact factor: 3.843

10.  In silico simulation of corticosteroids effect on an NFkB- dependent physicochemical model of systemic inflammation.

Authors:  Panagiota T Foteinou; Steve E Calvano; Stephen F Lowry; Ioannis P Androulakis
Journal:  PLoS One       Date:  2009-03-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.